3 8 T H A N N U A L

M E E T I N G

A N D S C I E N T I F I C

S E S S I O N S

C A L L F O R A B S T R A C T S

INTERNATIONAL

SOCIETY

FOR HEART

AND LUNG

TRANSPLANTATION

APRIL

1 1 - 1 4

2 0 1 8

CONVENING AT

THE ACROPOLIS

CONGRESS

CENTER

NICE, FRANCE

CALL FOR ABSTRACTS

$25.ABSTRACT SUBMISSION FEE

ABSTRACT SUBMISSION SITE: ishlt.org/meetings/abstracts.asp

ABSTRACT SUBMISSION SITE OPENS: August 1, 2017

ABSTRACT SUBMISSION DEADLINE: October 24, 2017, 11:59 PM EDT

ABSTRACT STATUS NOTIFICATION DATE: December 20, 2017

For Technical Support of Electronic Abstract Submission, CTI MEETING TECHNOLOGIESMonday – Friday7:00 am – 6:00 pm Central Time (USA)Phone: 217-398-1792Email: ishlt@support.ctimeetingtech.com

For General Guideline Inquiries Regarding Abstract Submission,ISHLTMonday – Friday8:30 am – 4:30 pm Central Time (USA)Phone: 972-490-9495Email: communications@ishlt.org Web: www.ishlt.org

[ 1 ]

A MESSAGE FROM THE 2018 SCIENTIFIC

PROGRAM CHAIR

[ 2 ]

[ 3 ]

Dear Colleague:

On behalf of Andrew Fisher, President of the International Society for Heart and Lung Transplantation,

the ISHLT Board of Directors and the 2018 Scientific Program Committee, I have the honor of inviting

you to attend the Society’s 38th Annual Meeting and Scientific Sessions to be held on April 11-14, 2018

in the lovely city of Nice in Southern France.

For this meeting, we return to The Acropolis Congress Center nestled in the heart of Nice, just 15 minutes

from the airport.

We hope to build on the tremendous success of the 2017 Annual Meeting in San Diego, CA, USA,

the best attended annual meeting in our Society’s history, by continuing to offer both research presentation

sessions and 31 exciting symposia throughout all four days of the Nice Meeting.

The majority of the meeting will be devoted to submitted scientific content. In anticipation of your

contribution of high quality, novel scientific work, we plan to schedule a total of 54 oral sessions to show-

case work described in the highest scoring submitted abstracts. In addition, mini-oral sessions and

general poster sessions are planned to share research with all attendees.

Abstracts will only be accepted online. A link to the abstract submission site is available on the ISHLT

website (ishlt.org/meetings/abstracts.asp). The abstract submission deadline is October 24, 2017 at

11:59 PM Eastern Daylight (North America) Time.

We especially encourage the submission of work by your trainees and young investigators, the best of

which will continue to be highlighted in the Philip Caves Award competition, the Nursing, Health

Science and Allied Health Excellence in Research Award competition, the Early Career Scientist Award

in Transplantation competition, the Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation:

The Best of the Best Award competition (see details in this brochure), and as featured abstracts and posters.

I look forward to receiving your abstract submissions and welcoming you all to Nice, France, for the

38th ISHLT Annual Meeting and Scientific Sessions!

With best regards,

Christian Benden, MD FCCP

ISHLT 38th Annual Meeting Scientific Program Chair

This is your guide to submitting

an abstract for the ISHLT 38th

Annual Meeting and Scientific

Sessions April 11-14, 2018 in

Nice, France.

ABSTRACT SUBMISSION

INSTRUCTIONS

[ 4 ]

Please read these instructions prior to beginning the submission processto understand all guidelines and rules applying to abstract submission.Submitters will be able to access complete submission instructions andguidelines, including character, image, table and/ or graphic limits, viathe online submission site.

ABSTRACT SUBMISSION SITE:The Abstract Submission System is now live on the ISHLT website(ishlt.org/meetings/abstracts.asp). All abstracts must be submitted online.

ABSTRACT SUBMISSION FEE:There is a $25.00 non-refundable processing fee for each abstract submission. This modest fee was approved by the ISHLT Board of Directorsto avoid an increase in meeting registration fees and to defray annualmeeting costs.

SUBMISSION AREAS:There are 3 areas in which to submit an abstract (scroll down for infor-mation and instructions to submit an abstract into any of these areas).Each abstract may only be submitted in ONE of these areas. Please notethat there is a separate submission link for each area.

A: General Abstracts

B: Junior Faculty Clinical Case Reports

C: Late Breaking Clinical Science

The Abstract Submission deadline for allareas is October 24, 2017, 11:59 PM EDT.

BASIC SCIENCE AND TRANSLATIONAL RESEARCH (BSTR)BSTR – Immunology, Inflammation, ImmunosuppressionBSTR – Models of Organ Preservation, Perfusion and Graft InjuryBSTR – Xenotransplantation/Regenerative Medicine/Artificial OrgansBSTR – Other

ECONOMICS, ETHICS, PUBLIC POLICY (EEP)EEP – HeartEEP – LungEEP – MCSEEP – Other

HEART FAILURE - ADULT (HF)HF – Patient Care PathwaysHF – Quality of LifeHF – Therapeutics and PharmacologyHF – Other

HEART TRANSPLANTATION - ADULT (HTX)HTX – Acute RejectionHTX – Clinical Ex-Vivo Heart Perfusion and PreservationHTX – Coronary Artery VasculopathyHTX – Diagnostics/Patient ManagementHTX – Donor Management and Organ AllocationHTX – Immunosuppression, Therapeutics and PharmacologyHTX – Infectious DiseasesHTX – Primary Graft DysfunctionHTX – Quality of LifeHTX – Other

GENERAL ABSTRACTS

[ 5 ]

S U B M I S S I O N A R E A

General Abstracts may be submitted in one of the following categories:

INFECTIOUS DISEASES (ID)ID – HeartID – LungID – MCSID – Pediatrics

LUNG TRANSPLANTATION – ADULT (LTX)LTX – Acute RejectionLTX – Candidate Selection for Advanced TherapiesLTX – Chronic Lung Allograft DysfunctionLTX – Clinical Ex-Vivo Lung Perfusion and PreservationLTX – Diagnostics/Patient ManagementLTX – Donor Management and Organ AllocationLTX – Immunosuppression, Therapeutics and PharmacologyLTX – Infectious DiseasesLTX – Lung FailureLTX – Primary Graft DysfunctionLTX – Quality of LifeLTX – Other

MECHANICAL CIRCULATORY SUPPORT - ADULT (MCS)MCS – Complications Bleeding/ThrombosisMCS – Complications InfectionMCS – Complications OtherMCS – Devices and EngineeringMCS – Patient SelectionMCS – Physiology and Patient ManagementMCS – Quality of LifeMCS – Surgical TechniquesMCS – Therapeutics and PharmacologyMCS – Other

NURSING, HEATH SCIENCE, ALLIED HEALTH (NHSAH)NHSAH – Allied HealthNHSAH – NursingNHSAH – Quality of LifeNHSAH – Social ScienceNHSAH – Symptom Management/Self-Care

PATHOLOGY (PATH)PATH – HeartPATH – Lung

PEDIATRICS (PEDS)PEDS – Heart FailurePEDS – Heart TransplantationPEDS – Lung PEDS – MCS

[ 6 ]

GENERAL ABSTRACTS

[ 7 ]

PHARMACY AND PHARMACOLOGY (PHARM)PHARM – HeartPHARM – LungPHARM – MCS

PULMONARY HYPERTENSION (PH)PH – Chronic Thromboembolic Pulmonary Hypertension (CTEPH)PH – Quality of LifePH – Pulmonary Arterial HypertensionPH – Pulmonary Hypertension due to Heart or Lung DiseasePH – Physiology/RV Failure/ComplicationsPH – Therapeutics and PharmacologyPH – Other

NOTE: Submission of the same abstract into different categories is not permitted. Submission of onestudy as several different abstracts is not permitted. If the abstracts in question are not differentenough to be considered separate studies, or if the same abstract is submitted into multiple cat-egories, all versions may be rejected.

The content for GENERAL ABSTRACTS should include:

i. Brief statement of purpose of the study (goal or hypothesis being tested)

ii. Statement of methods and procedures used

iii. Summary of results, presented in sufficient detail to support the conclusion

iv. Conclusion

Please use the General Abstracts submission link (found on the main page of the submis-sion site) to submit an abstract in this area.

SUBMIT AN ABSTRACT: ishlt.org/meetings/abstracts.asp

GENERAL ABSTRACTS

JUNIOR FACULTY CLINICAL CASE REPORTS (CASE)CASE – Heart Failure/TransplantationCASE – Infectious DiseasesCASE – Lung Failure/TransplantationCASE – Mechanical Circulatory SupportCASE – PediatricsCASE – Pulmonary Hypertension

The best scored case reports will be selected for presentation in the Junior Faculty Clinical CaseDilemmas in Thoracic Transplantation: Best Presentation oral session. Other well-scored reportswill be selected for presentation in the Junior Faculty Clinical Case Reports Poster Session.

NOTE: Case reports accepted for oral presentation will be published in the Journal of Heart and Lung Transplantation. Case reports accepted for poster presentation will NOT be published in the Journal of Heartand Lung Transplantation.

The content for JUNIOR FACULTY CLINICAL CASE REPORTS should include:

i. Introduction

ii. Case Report

iii. Summary

Please use the Junior Faculty Clinical Case Report (JFCCR) submission link (found on themain page of the submission site) to submit an abstract in this area.

SUBMIT AN ABSTRACT: ishlt.org/meetings/abstracts.asp

[ 8 ]

JUNIOR FACULTY

S U B M I S S I O N A R E A

Junior Faculty (defined as an individual whoseformal professional training was completedfive or less years ago) and trainees are eligible to submit case reports in one of the followingcategories:

[ 9 ]

LATE BREAKINGCLINICAL SCIENCE

S U B M I S S I O N A R E A

The Late Breaking Clinical Science abstract category is intended to facilitate the presentation ofhigh impact multi-center studies or particularly provocative single center investigations. In general, suchstudies would include prospective, randomized trials that seek to investigate new approaches to the diagnosis and/or treatment of cardiothoracic diseases relevant to the field and that have the potentialto alter our contemporary treatment paradigm.

Abstracts presenting an interim analysis of clinical trial data will not be accepted unless the intentionto conduct an interim analysis was predetermined in the trial protocol before the study commenced.

The content for LATE BREAKING CLINICAL SCIENCE abstracts should include:

i. Summary of objectives

ii. Methods

iii. Endpoints

Please use the Late Breaking Clinical Science (LBCS) submission link (found on the main page fo thesubmission site) to submit an abstract in this area. The abstract submitted by the October 24, 2017deadline will serve as a placeholder for the final abstract.

Final analysis of the study results and conclusions MUST be submitted to Susie Newton (susie.newton@ishlt.org) at the ISHLT headquarters by March 14, 2018. Failure to submit this databy the deadline may result in the withdrawal of the abstract from the program. This analysis will beseen only by a closed panel to ensure complete confidentiality of the results prior to presentation. Theprogram committee chair in consultation with the program committee reserves the final decision regardingscheduling of Late Breaking Clinical Science presentations. An invitation to give a presentation basedon a submitted abstract cannot be withdrawn simply because the results do not conform to expectations.

NOTE: If you wish to have a revised version of your abstract with more detailed study findings published inthe abstract supplement to the JHLT, ISHLT MUST receive a revised version of the abstract reflecting themore detailed findings NO LATER THAN January 26, 2018.

SUBMIT AN ABSTRACT: ishlt.org/meetings/abstracts.asp

To assure that truly “late breaking” information is included in the meet-ing, authors may submit abstracts describing trials and studies that arenot yet completed as of October 24, 2017 but WILL have results andconclusions available by March 14, 2018. Studies which have resultsand conclusions by October 24, 2017 will not be considered latebreaking and should be submitted in one of the General Abstract categories.

ABSTRACT SUBMISSION

POLICIES

[ 10 ]

All abstracts must be submitted online at:

http://ishlt.org/meetings/abstracts.asp

Submitting authors will be able to access complete submission

instructions and guide lines, including character, image, table

and/or graphic limits, via the online submission site.

The person indicated as presenting author during abstract

submission will be the sole point of contact for information regard-

ing the submission and is responsible for notifying all co-authors

regarding the outcome of the abstract submission and any

changes to the program, as corresponded by the ISHLT, in a

timely manner.

Accepted abstracts sub mitted in the General Abstracts or Late

Breaking Clinical Trials areas will be published in the 2018 April

Supplement of the Journal of Heart and Lung Transplantation. Case Reports submitted in the Junior Faculty Clinical Case Reports

area and accepted for oral presentation will be published in

the Journal of Heart and Lung Transplantation. Case Reports

submitted in the Junior Faculty Clinical Case Reports area and

accepted for poster presentation will NOT be published in the

Journal of Heart and Lung Transplantation. Accepted abstracts

will be published exactly as submitted, so all content and author

information should be reviewed carefully before submission.

Previous Publication of Abstracts: Research based on an

accepted abstract may not be presented if the abstract is

published as an article prior to April 11, 2018.

1

2

3

4

[ 11 ]

The person indicated

as presenting author

during abstract

submission will be

the sole point of

contact for

information regarding

the submission.

Revisions of a submitted abstract can be made up until

the submission deadline of October 24, 2017, 11:59 PM EDT.

After this deadline, the submission site will close and no changes

to the abstract, including the author information, can be made.

Submission of an abstract signifies that the abstract

author(s) have given permission for the abstract to be repro-

duced in print in the Journal of Heart and Lung Transplantation and

in digital formats of ISHLT’s choosing for distribution and/or

sale by ISHLT.

Acceptance of an invitation to give a presentation based on

a submitted abstract signifies that the presenter has given per-

mission for the presentation to be recorded in digital formats

of ISHLT’s choosing for distribution and/or sale by ISHLT.

Any abstract author who accepts an invitation to give a

presentation based on a submitted abstract agrees to present

the data described in the abstract and may not present data

not described in the abstract. Any presenter who does not

present the data described in the abstract and/or declines

the presentation invitation without arranging for the presen-

tation to be given by an abstract co-author (pending approval

of ISHLT), will be appropriately sanctioned from future partic-

ipation in ISHLT meetings by the Society’s Board of Directors.

Informed Consent: Submission of an abstract signifies that

the author(s) agree and confirm that their study involving

human subjects adheres to the principles of the:

• Declaration of Helsinki of the World Medical Association

• ISHLT Statement on Transplant Ethics

5

6

7

8

9

[ 12 ]

Compliance with Declaration of Istanbul: Submission of

an abstract signifies that the author(s) agree and confirm that

their study involving human subjects adheres to the principles

of the:

• Declaration of Istanbul

• ISHLT Statement on Transplant Ethics

IMPORTANT: Due to ongoing concerns about compliance with

the Declaration of Istanbul and the ISHLT Statement on Trans-

plant Ethics, abstracts related to transplantation and involving

either organs or tissue from human donors in China will not

be accepted for consideration to the 2018 Annual Meeting.

This policy will be reviewed on an annual basis.

Use of Animals: Submission of an abstract signifies that

the author(s) agree and confirm that their study involving the

use of animals conforms fully within current NIH, EU or anal-

ogous national guidelines for the care and use of animals.

Use of Institutional Names and Commercial Trade Names:

For purposes of blind scoring, institutional names must be

omitted whenever possible in the title and body of the ab-

stract. Authors are requested to avoid the use of commercially

branded names of medications or devices. If a specific med-

ication/device is only identifiable by its trade name, then this

should appear in 3 brackets after a generic description of the

medication/device.

11

12

10

[ 13 ]

For purposes of

blind scoring,

institutional names

must be omitted

whenever possible

in the title and body

of the abstract.

Content Validity and Fair Balance: Authors are required

to prepare fair and balanced presentations that are objective

and scientifically rigorous. All recommendations involving clin-

ical medicine must be based on evidence that is accepted

within the profession of medicine as adequate justification for

their indications and contraindications in the care of patients.

All scientific research referred to, reported or used in support

or justification of a patient care recommendation must con-

form to the generally accepted standards of experimental de-

sign, data collection and analysis.

Use of Generic vs. Trade Names: Abstracts must use sci-

entific or generic names when referring to products. Should it

be necessary to use a trade name, then the trade names of

all similar products or those within a class must be used.

Commercial Influence: Presenters of research based on

accepted abstracts are not permitted to receive any travel,

hotel or registration stipends or other financial assistance re-

lated to the ISHLT 2018 Annual Meeting from any company

whose products or services are discussed in the presentation.

Presenters of research based on accepted abstracts may not

receive direct input regarding the content of the presentation

from any company whose products or services are discussed

in the presentation.

Rules for Employees of Commercial Interests: Employees,

owners and patent holders of a commercial interest are gen-

erally not permitted to serve as the first author, presenting au-

thor, senior author or primary author of an abstract. In rare

circumstances where the work does not involve any academic

13

14

15

16

[ 14 ]

collaborators, exceptions to this policy MAY be considered

on a case by case basis. After all abstracts have been se-

lected, ISHLT will initiate this process by communicating with

the primary author of any abstracts which list an industry em-

ployee, owner or patent holder as first author, presenting au-

thor, senior author or primary author of an abstract.

Conflict of Interest Disclosure: Disclosure of all relevant

financial relationships is required by all abstract authors. Full

and complete disclosure for EVERY author must be submitted

with the abstract. It is the responsibility of the individual sub-

mitting the abstract to obtain and provide complete and ac-

curate disclosure information for each author listed on an

abstract. Each individual author is responsible for the accu-

racy and completeness of the disclosure information submitted

on his/her behalf.

If no relevant financial relationships exist for a given author, this

must be stated. Failure to provide complete disclosure informa-

tion will result in disqualification from participation in the ed-

ucational activity. This requirement is intended neither to imply

any impropriety of such relationships nor to prejudice any indi-

vidual presenter or author. It is merely to identify such rela-

tionships through full disclosure and to allow ISHLT to assess and

resolve potential influences on the educational activity prior to

the planning and implementation of an educational activity.

17

[ 15 ]

Disclosure of all

relevant financial

relationships is

required by all abstract

authors with full and

complete disclosure

for every author listed

on an abstract.

Financial relationships are those relationships in which the individual benefitsby receiving a salary, royalty, intellectual property rights, consulting fee, hono-raria for promotional speakers’ bureau, ownership interest (e.g., stocks, stockoptions or other ownership interest, excluding diversified mutual funds), or otherfinancial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contractedresearch), consulting, speaking and teaching, membership on advisory committeesor review panels, board membership, and other activities from which remunerationis received, or expected. ACCME considers relationships of the person involvedin the CME activity to include financial relationships of a spouse or partner. TheACCME has not set a minimum dollar amount for relationships to be significant.Inherent in any amount is the incentive to maintain or increase the value of therelationship.

With respect to personal financial relationships, contracted research includes research funding where the institution gets the grant and manages the fundsand the person is the principal or named investigator on the grant.

Circumstances create a conflict of interest when an individual has an opportunityto affect CME content about products or services of a commercial interest withwhich he/she has a financial relationship. The ACCME considers financial rela-tionships to create actual conflicts of interest in CME when individuals have botha financial relationship with a commercial interest and the opportunity to affectthe content of CME about the products or services of that commercial interest.The ACCME considers “content of CME about the products or services of thatcommercial interest” to include content about specific agents/devices, but notnecessarily about the class of agents/devices, and not necessarily content aboutthe whole disease class in which those agents/devices are used. With respect tofinancial relationships with commercial interests, when a person divests them-selves of a relationship it is immediately not relevant to conflicts of interest but itmust be disclosed to the learners for 12 months.

A commercial interest is any entity producing, marketing, re-selling, or distrib-uting health care goods or services consumed by, or used on, patients. TheACCME does not consider government agencies or providers of clinical servicedirectly to patients to be commercial interests.

Abstract Reviewers, Board Members, Committee Members, Scientific Council Operating Board Members and Workforce Members, Taskforce Participants, Authors, and Guidelines Developers are not permitted to receive any direct remuneration or gifts from any commercial entities for any activity in which theyare an official representative or a participant on behalf of the Society, norshould they be subject to direct input from a commercial supporter regardingany such activity.

[ 16 ]

Definitions:Financial

Relationships:

ContractedResearch:

Conflict ofInterest:

CommercialInterest:

CommercialSupporter Influence:

Abstract ReviewAfter the submission deadline, completed abstracts will be peer reviewed.Incomplete abstracts cannot be processed and will not be reviewed. Toensure the integrity of the review process, revisions will not be acceptedafter the submission deadline – no exceptions. All abstracts will beblinded for review, i.e. reviewed without knowledge of the author(s),institution(s) or disclosure information; therefore, as indicated in theabove policies, abstract content should not include the authors,institution information or commercial trade names.

Notification of Acceptance or RejectionPresenting authors of all submitted abstractswill receive a status notification of acceptanceor rejection no later than December 20, 2017.

On January 8, 2018,presenting authors of all accepted abstracts will receive a presentationinvitation including pre sentationdate, session assignment andformat (oral, mini oral orposter presentation).

All presentations must be confirmed by January 26,2018.

WithdrawalsWithdrawal of an abstract from the program

should occur only in exceptional circumstances, aswithdrawal of an accepted abstract deprives

another team of investigators of the valued opportunityto present. The presenting author of an accepted

abstract may withdraw their abstract by following theappropriate link in the presentation invitation. All with-

drawals must include the reason for withdrawal and thepresenting author must confirm that the decision was made

collectively by all co-authors.

Withdrawal deadline: January 26, 2018

ISHLT reserves the right to withdraw abstracts that are in violationof the Society’s policies and guidelines outlined in this document.

[ 17 ]

ABSTRACT AWARDS

• Philip K. Caves Award

• Nursing, Health Science, and Allied Health Excellence in Research Award

• Early Career Scientist Award in Transplantation

• Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award

[ 18 ]

This award is named after the clinician who developed and pioneered the technique of transve-nous endomyocardial biopsy to assess for rejection after cardiac transplantation. Established in1982 to encourage and reward original high quality research performed by trainees, residents,fellows and graduate students, this $1,000 award is bestowed annually on the trainee/resident/fellow/student whose oral presentation is judged to be the best at the Philip K. Caves Award Session at the Annual Scientific Meeting. The online submission process includes an area to indicate that you wish to have your abstract considered for this award.

Eligibility Requirements:

• Applicant must be a Student/Resident/Fellow/Scientist in training

• Applicant must be first author and presenter

• Applicant must be a current ISHLT member or be working under a current ISHLT member

• Applicant must not have previously won this award

PHILIP K. CAVES AWARD

[ 19 ]

This award was established in 2005 to recognize excellence in Nursing, Health Science andAllied Health research and to encourage original investigation and professional excellence in thepreparation of scientific papers. This award honors an outstanding contribution by a nurse, phar-macist, social scientist, or other allied health professional whose work makes an important contribution to the field. This $1,000 award is bestowed annually on the nurse, pharmacist, socialscientist, or other allied health professional whose oral presentation is judged to be the best atthe Annual Scientific Meeting. The online submission process includes an area to indicate thatyou wish to have your abstract considered for this award.

Eligibility Requirements:

• Applicant must be a nurse, pharmacist, social scientist, or other allied health professional

• Applicant must be first author and presenter

• Applicant must be a current ISHLT member

• Applicant must not have previously won this award

NURSING, HEALTH SCIENCE AND ALLIEDHEALTH EXCELLENCE IN RESEARCH AWARD

[ 20 ]

This Basic Science award aims to recognize an excellent abstract in the field of basic andtranslational science with the goal of encouraging scientists in the early stages of their careersto submit their work for presentation at the ISHLT Annual meeting. Five finalists will be selectedto present their abstracts during a session at the meeting, and the Annual Meeting registrationfee will be waived for these finalists. The winner will receive $1,000 and complimentary mem-bership to ISHLT for the remainder of the year, and the winner will be announced during theAwards Presentations in the final Plenary Session. The winner must attend this session in personto receive the award. The online abstract submission process includes an area to indicate thatyou wish to have your abstract considered for this award.

Eligibility Requirements:

• Applicant must be a trainee scientist/medical student not holding a medical degree, nurse, or pharmacist

• Applicant must NOT be a post-graduate clinician/trainee and/or hold a faculty position

• Applicant must be first author and presenter

• Applicant must submit their abstract into one of the Basic Science and Translational Research categories during abstract submission

• ISHLT membership is not required for the applicant or chief

• Applicant must not have previously won this award

[ 21 ]

EARLY CAREER SCIENTIST AWARD IN TRANSPLANTATION

To recognize the outstanding contributions by junior faculty and trainees, the ISHLT JuniorFaculty and Trainees Council sponsors a session each year at the Annual Meeting entitled,Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best. Casesare submitted by junior faculty and trainees using the specific JFCCR online abstract submissionlink, and the top scoring case reports are selected for presentation in this session. Expert seniorclinicians are invited to discuss the intricacies of these cases and share clinical pearls. At theconclusion of the session, the best case presentation is selected by a panel of judges and thepresenter is awarded complimentary registration to the next ISHLT Annual Meeting.

JUNIOR FACULTY CLINICAL CASE DILEMMASIN THORACIC TRANSPLANTATION BESTPRESENTATION AWARD

[ 22 ]

ISHLT offers the opportunity for eligible presentingauthors to apply for a $1,000 Annual Meeting TravelGrant to attend the 2018 Annual Meeting if theirwork is selected for oral or mini oral presentation.

The eligible applicant must be a current member ofISHLT or, if in training, must be in training under acurrent member of ISHLT.

Eligible candidates must come from one of the following groups:

• SCIENTISTS (NON-CLINICAL) who are working in a University or equivalent research institution and who are not appointed to a tenured track.

• NURSES, SOCIAL SCIENTISTS,

ALLIED HEALTH PROFESSIONALS

AND PHARMACISTS

• CLINICAL FELLOWS who are undergoing theirtraining in geographic areas outside North America,Western Europe, Australia and Japan.

A link to the travel grant application form will be includedin oral and mini oral presentation invitations sent on January 8, 2018.

TRAVELGRANTS

[ 23 ]

REGISTRATION & HOUSING

Submission or acceptance of an abstract does not

register you or ensure hotel accommodations for

the Annual Meeting. All presenting authors of

abstract research are required to register and pay

the appropriate registration fees and arrange

their own hotel accommodations. Scheduled

abstract sessions and presentation times will not

be changed to accommodate travel schedules.

[ 24 ]

This meeting will be ACCME, ACPE,ANCC and ABTC accredited.

Details will be provided in the ISHLT2018 Preliminary Program available

in October.

Registration Fees

Hotel Reservations

ISHLT will arrange for discounted rates atvarious local hotels near The Acropolis Congress

Centre. To receive the ISHLT group rate, youmust make hotel reservations using the official

reservation link which will be published in theISHLT 2018 Preliminary Program available in

October.

CE Accreditation:

[ 25 ]

The registration fee includes admittance into Symposia, Plenary Sessions, Oral Sessions, Mini Oral Sessions, PosterSessions and the Exhibit Hall. It also includes coffeebreaks each day, the Exhibit Hall Opening Receptionand wine and cheese receptions in the poster hall.

FOR BUDGETING PURPOSES, WE HAVE INCLUDEDTHE 2017 ADVANCE REGISTRATION FEES (BELOW) TO USE AS A MINIMUM GUIDELINE.

2017 ADVANCE REGISTRATION FEESIndustry Member $1020Industry Non-Member $1355Physician/Surgeon Member $ 795Physician/Surgeon $1130Non-MemberAllied Health/ $ 465Non-Physician MemberAllied Health/Non-Physician $ 800Non-MemberStudent/Trainee Member $ 355Student/Trainee Non-Member $ 520

PLEASE NOTE: ACTUAL FEES WILL BE POSTED INTHE ISHLT 2018 PRELIMINARY PROGRAM INOCTOBER AND WILL INCLUDE VAT TAX.

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION14673 Midway Road, Suite 200, Addison, Texas 75001

38th ANNUAL MEETING AND SCIENTIFIC SESSIONS

NICE, FRANCEApril 11-14, 2018